Home » Modern Medicine » Bariatrics » lorcaserin



An anorexigenic agent that is a novel selective agonist of the serotonin 2C, which was approved by the FDA in 2012 (after after a 2010 thumbs down) for managing obesity in patients with a BMI of more than 30 or with a BMI over 27 and one or more obesity-related co-morbidities–e.g., hypertension, hypercholesterolaemia, or type 2 diabetes.

Adverse effects Headache, dizziness and nausea. 

The FDA voted against approving lorcaserin in 2010 due to concerns about tumourgenesis in rats and its marginal efficacy.

Proprietary name Belviq 

Reference http://en.wikipedia.org/wiki/Lorcaserin


Leave A Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.